Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
11
AKTX Quote, Financials, Valuation and Earnings
Last price:
$0.33
Seasonality move
:
-24.17%
Day range:
$0.32 - $0.36
52-week range:
$0.29 - $1.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.54x
Volume:
509.6K
Avg. volume:
933.6K
1-year change:
-73.85%
Market cap:
$12.2M
Revenue:
--
EPS (TTM):
-$0.39
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AKTX
Akari Therapeutics Plc
|
-- | -$0.11 | -- | -53.67% | $4.53 |
|
AUTL
Autolus Therapeutics Plc
|
$21.3M | -$0.23 | 84624.25% | -288.08% | $9.52 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
CLLS
Cellectis SA
|
$9.6M | -$0.10 | -5.7% | -56.58% | $7.20 |
|
DBVT
DBV Technologies SA
|
$889.9K | -$0.34 | -- | -77.25% | $20.57 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AKTX
Akari Therapeutics Plc
|
$0.34 | $4.53 | $12.2M | -- | $0.00 | 0% | -- |
|
AUTL
Autolus Therapeutics Plc
|
$1.57 | $9.52 | $417.8M | -- | $0.00 | 0% | 8.15x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$5.09 | $17.94 | $3.2M | -- | $0.00 | 0% | 0.73x |
|
CLLS
Cellectis SA
|
$4.83 | $7.20 | $484.6M | -- | $0.00 | 0% | 6.01x |
|
DBVT
DBV Technologies SA
|
$13.05 | $20.57 | $357.1M | -- | $0.00 | 0% | -- |
|
NCNA
NuCana Plc
|
$4.43 | $104.00 | $18.4M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AKTX
Akari Therapeutics Plc
|
8.54% | -2.620 | 6.43% | 0.16x |
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 3.892 | 74.96% | 4.83x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.246 | -- | 1.20x |
|
CLLS
Cellectis SA
|
54.27% | 0.665 | 41.7% | 1.35x |
|
DBVT
DBV Technologies SA
|
23.24% | -1.892 | 5.85% | 1.41x |
|
NCNA
NuCana Plc
|
0.52% | -0.585 | 0.95% | 4.03x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AKTX
Akari Therapeutics Plc
|
-- | -$2.2M | -82.46% | -92.06% | -- | -$2.1M |
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
CLLS
Cellectis SA
|
$30M | $5.9M | -15.69% | -31.08% | 16.76% | -$4M |
|
DBVT
DBV Technologies SA
|
-$4.3M | -$36.9M | -211.46% | -280.59% | -- | -$32.5M |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
Akari Therapeutics Plc vs. Competitors
-
Which has Higher Returns AKTX or AUTL?
Autolus Therapeutics Plc has a net margin of -- compared to Akari Therapeutics Plc's net margin of -373.3%. Akari Therapeutics Plc's return on equity of -92.06% beat Autolus Therapeutics Plc's return on equity of -59.51%.
Company Gross Margin Earnings Per Share Invested Capital AKTXAkari Therapeutics Plc-- -$0.19 $24.8M AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M -
What do Analysts Say About AKTX or AUTL?
Akari Therapeutics Plc has a consensus price target of $4.53, signalling upside risk potential of 1233.33%. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.52 which suggests that it could grow by 506.51%. Given that Akari Therapeutics Plc has higher upside potential than Autolus Therapeutics Plc, analysts believe Akari Therapeutics Plc is more attractive than Autolus Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings AKTXAkari Therapeutics Plc1 0 0 AUTLAutolus Therapeutics Plc9 0 0 -
Is AKTX or AUTL More Risky?
Akari Therapeutics Plc has a beta of 0.279, which suggesting that the stock is 72.076% less volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 2.013, suggesting its more volatile than the S&P 500 by 101.348%.
-
Which is a Better Dividend Stock AKTX or AUTL?
Akari Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics Plc pays -- of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKTX or AUTL?
Akari Therapeutics Plc quarterly revenues are --, which are smaller than Autolus Therapeutics Plc quarterly revenues of $21.1M. Akari Therapeutics Plc's net income of -$6.4M is higher than Autolus Therapeutics Plc's net income of -$78.6M. Notably, Akari Therapeutics Plc's price-to-earnings ratio is -- while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics Plc is -- versus 8.15x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKTXAkari Therapeutics Plc-- -- -- -$6.4M AUTLAutolus Therapeutics Plc8.15x -- $21.1M -$78.6M
-
Which has Higher Returns AKTX or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -- compared to Akari Therapeutics Plc's net margin of --. Akari Therapeutics Plc's return on equity of -92.06% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital AKTXAkari Therapeutics Plc-- -$0.19 $24.8M BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About AKTX or BDRX?
Akari Therapeutics Plc has a consensus price target of $4.53, signalling upside risk potential of 1233.33%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 3394.13%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Akari Therapeutics Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Akari Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings AKTXAkari Therapeutics Plc1 0 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is AKTX or BDRX More Risky?
Akari Therapeutics Plc has a beta of 0.279, which suggesting that the stock is 72.076% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.955, suggesting its less volatile than the S&P 500 by 4.507%.
-
Which is a Better Dividend Stock AKTX or BDRX?
Akari Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics Plc pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKTX or BDRX?
Akari Therapeutics Plc quarterly revenues are --, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. Akari Therapeutics Plc's net income of -$6.4M is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, Akari Therapeutics Plc's price-to-earnings ratio is -- while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics Plc is -- versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKTXAkari Therapeutics Plc-- -- -- -$6.4M BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns AKTX or CLLS?
Cellectis SA has a net margin of -- compared to Akari Therapeutics Plc's net margin of 1.68%. Akari Therapeutics Plc's return on equity of -92.06% beat Cellectis SA's return on equity of -31.08%.
Company Gross Margin Earnings Per Share Invested Capital AKTXAkari Therapeutics Plc-- -$0.19 $24.8M CLLSCellectis SA85.76% $0.01 $219.7M -
What do Analysts Say About AKTX or CLLS?
Akari Therapeutics Plc has a consensus price target of $4.53, signalling upside risk potential of 1233.33%. On the other hand Cellectis SA has an analysts' consensus of $7.20 which suggests that it could grow by 49.07%. Given that Akari Therapeutics Plc has higher upside potential than Cellectis SA, analysts believe Akari Therapeutics Plc is more attractive than Cellectis SA.
Company Buy Ratings Hold Ratings Sell Ratings AKTXAkari Therapeutics Plc1 0 0 CLLSCellectis SA2 2 0 -
Is AKTX or CLLS More Risky?
Akari Therapeutics Plc has a beta of 0.279, which suggesting that the stock is 72.076% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.818, suggesting its more volatile than the S&P 500 by 181.784%.
-
Which is a Better Dividend Stock AKTX or CLLS?
Akari Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics Plc pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKTX or CLLS?
Akari Therapeutics Plc quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $35M. Akari Therapeutics Plc's net income of -$6.4M is lower than Cellectis SA's net income of $586.4K. Notably, Akari Therapeutics Plc's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics Plc is -- versus 6.01x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKTXAkari Therapeutics Plc-- -- -- -$6.4M CLLSCellectis SA6.01x -- $35M $586.4K
-
Which has Higher Returns AKTX or DBVT?
DBV Technologies SA has a net margin of -- compared to Akari Therapeutics Plc's net margin of --. Akari Therapeutics Plc's return on equity of -92.06% beat DBV Technologies SA's return on equity of -280.59%.
Company Gross Margin Earnings Per Share Invested Capital AKTXAkari Therapeutics Plc-- -$0.19 $24.8M DBVTDBV Technologies SA-- -$1.21 $68.9M -
What do Analysts Say About AKTX or DBVT?
Akari Therapeutics Plc has a consensus price target of $4.53, signalling upside risk potential of 1233.33%. On the other hand DBV Technologies SA has an analysts' consensus of $20.57 which suggests that it could grow by 57.62%. Given that Akari Therapeutics Plc has higher upside potential than DBV Technologies SA, analysts believe Akari Therapeutics Plc is more attractive than DBV Technologies SA.
Company Buy Ratings Hold Ratings Sell Ratings AKTXAkari Therapeutics Plc1 0 0 DBVTDBV Technologies SA3 0 1 -
Is AKTX or DBVT More Risky?
Akari Therapeutics Plc has a beta of 0.279, which suggesting that the stock is 72.076% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.102, suggesting its less volatile than the S&P 500 by 210.179%.
-
Which is a Better Dividend Stock AKTX or DBVT?
Akari Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics Plc pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKTX or DBVT?
Akari Therapeutics Plc quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Akari Therapeutics Plc's net income of -$6.4M is higher than DBV Technologies SA's net income of -$33M. Notably, Akari Therapeutics Plc's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics Plc is -- versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKTXAkari Therapeutics Plc-- -- -- -$6.4M DBVTDBV Technologies SA-- -- -- -$33M
-
Which has Higher Returns AKTX or NCNA?
NuCana Plc has a net margin of -- compared to Akari Therapeutics Plc's net margin of --. Akari Therapeutics Plc's return on equity of -92.06% beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital AKTXAkari Therapeutics Plc-- -$0.19 $24.8M NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About AKTX or NCNA?
Akari Therapeutics Plc has a consensus price target of $4.53, signalling upside risk potential of 1233.33%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 469425.96%. Given that NuCana Plc has higher upside potential than Akari Therapeutics Plc, analysts believe NuCana Plc is more attractive than Akari Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings AKTXAkari Therapeutics Plc1 0 0 NCNANuCana Plc0 1 0 -
Is AKTX or NCNA More Risky?
Akari Therapeutics Plc has a beta of 0.279, which suggesting that the stock is 72.076% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.595, suggesting its more volatile than the S&P 500 by 59.472%.
-
Which is a Better Dividend Stock AKTX or NCNA?
Akari Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics Plc pays -- of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKTX or NCNA?
Akari Therapeutics Plc quarterly revenues are --, which are smaller than NuCana Plc quarterly revenues of --. Akari Therapeutics Plc's net income of -$6.4M is lower than NuCana Plc's net income of -$378.9K. Notably, Akari Therapeutics Plc's price-to-earnings ratio is -- while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics Plc is -- versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKTXAkari Therapeutics Plc-- -- -- -$6.4M NCNANuCana Plc-- -- -- -$378.9K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 0.06% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 2.97% over the past day.
